Sugi Predict

Sugi Predict / Compounds / SCHEMBL1502260

SCHEMBL1502260

SCHEMBL1502260

Cc1ccc(S(=O)(=O)OCCC(C)(C)CCOS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 2/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ GAA P10253 1/20 0.42
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ PSMD10 O75832 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12545957 0.95 STAT3 (0.42) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL31625997 0.93 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL6002078 0.89 ALDH1A1 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL31625882 0.88 CA12 (0.39) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL29171179 0.88 ALDH1A1 (0.42) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL23779385 0.86 CA12 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL21618125 0.86 ALDH1A1 (0.53) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL2057501 0.86 CA1 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL1438581 0.86 ALDH1A1 (0.49) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL29060128 0.86 STAT3 (0.44) STAT3ALDH1A1MEN1KMT2APSMD10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 — — US disclosed
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 — — US disclosed
US-20250248975-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2025-08-07 — — US disclosed
US-20250145611-A1 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. 2025-05-08 — — US disclosed
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 — — EP disclosed
WO-2024054851-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2024-03-14 — — WO disclosed
EP-4306111-A2 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-17 — — EP disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 — — WO disclosed
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 — — EP disclosed
US-20230067476-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2023-03-02 — — US disclosed
WO-2015165340-A1 ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE 南京明德新药研发股份有限公司 2015-11-05 — — WO disclosed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 — — US disclosed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 — — US disclosed
US-20140323740-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION (US) 2014-10-30 — — US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 — — US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 — — US disclosed
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 — — US disclosed
EP-2291187-A2 IDO INHIBITORS Newlink Genetics (US) 2011-03-09 — — EP disclosed
WO-2009132238-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-10-29 — — WO disclosed
WO-2009132238-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 STAT3 1590/4885ALDH1A1 2574/4885MEN1 4529/4885
US-20140323740-A1 IDO Inhibitors IDO1, IDO2, INMT STAT3 1657/4885ALDH1A1 983/4885MEN1 2262/4885
US-20110136796-A1 IDO Inhibitors IDO1, IDO2, INMT STAT3 1657/4885ALDH1A1 983/4885MEN1 2262/4885
US-20230067476-A1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF XDH, HTR1D, RXFP1 STAT3 3664/4885ALDH1A1 332/4885MEN1 1434/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 STAT3 990/4885ALDH1A1 1094/4885MEN1 4667/4885
US-20250145611-A1 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 STAT3 425/4885ALDH1A1 1500/4885MEN1 3097/4885
US-20250248975-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 STAT3 3338/4885ALDH1A1 3545/4885MEN1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.